The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients.

Autor: Schenk, PW, Vliet, M. van, Mathot, RAA, Gelder, T. van, Vulto, AG, Fessem, MAC van, Rij, S Verploegh-Van, Lindemans, J, Bruijn, JA, Schaik, RHN van
Předmět:
Zdroj: Pharmacogenomics Journal; Jun2010, Vol. 10 Issue 3, p219-225, 7p, 3 Charts, 1 Graph
Abstrakt: CYP2C19 converts the tricyclic antidepressant imipramine to its active metabolite desipramine, which is subsequently inactivated by CYP2D6. The novel CYP2C19*17 allele causes ultrarapid metabolism of CYP2C19 substrates. We genotyped 178 depressed patients on imipramine for CYP2C19*17, and measured steady-state imipramine and desipramine plasma concentrations. Mean dose-corrected imipramine plasma concentration was significantly dependent on CYP2C19 genotype (Kruskal–Wallis test, P=0.01), with circa 30% lower levels in CYP2C19*17/*17 individuals compared with CYP2C19*1/*1 (wild-type) patients. The mean dose-corrected imipramine+desipramine plasma concentrations and imipramine/desipramine ratios were not significantly different between genotype subgroups (Kruskal–Wallis tests, P0.12). In a multivariate analysis, we found a significant, but limited effect (P=0.035, η2=0.031) of the CYP2C19*17 genotype on imipramine+desipramine concentrations. Although the CYP2C19*17 allele is associated with a significantly increased metabolism of imipramine, CYP2C19*17 genotyping will, in our view, not importantly contribute to dose management of patients on imipramine therapy guided by imipramine+desipramine plasma concentrations. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: